Communiqués CervoMed Inc.

Actions

CRVO

US15713L1098

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
19,19 ^USD	-0,36%		+1,32%	+151,51%

29/05	CERVOMED INC. : JonesTrading Institutional Services relève sa recommandation à acheter	ZM
20/05	CervoMed nomme William Elder directeur financier	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CervoMed to Appoint William Elder as Chief Financial Officer	20/05	AQ
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates	15/05	AQ
CervoMed : Nominating and Corporate Governance Committee Charter	06/05	PU
CervoMed : Corporate Presentation April 2024	22/04	PU
CervoMed : Corporate Presentation April 2024	03/04	PU
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	01/04	AQ
CervoMed to Participate in Upcoming Investor Conferences	28/03	AQ
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors	28/03	AQ
CervoMed : Shareholder Meeting - Form 8-K	18/03	PU
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024	05/03	AQ
CervoMed to Participate in the BIO CEO and Investor Conference	21/02	AQ
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board	20/02	AQ
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	12/02	AQ
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board	07/02	AQ
CervoMed to Participate in the Emerging Growth Conference 67	05/02	AQ
CervoMed to Participate in the Emerging Growth Conference 66	05/01	AQ
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies	26/10/23	AQ
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias	25/10/23	AQ
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies	19/10/23	AQ
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference	06/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CervoMed Inc.

Actions

CRVO

US15713L1098

Communiqués

Filtres